ZP9830
Kv1.3 ion channel blocker targeting chronic inflammation
ZP9830 is a potent and selective Kv1.3 blocker with potential to treat a broad range of T-cell-driven autoimmune diseases.
Kv1.3 is a potassium conducting ion channel, which is selectively upregulated on T effector memory cells. T effector memory cells play a key role in autoimmunity and chronic inflammation by releasing pro-inflammatory cytokines, which drive tissue damage.
The anti-inflammatory effects of blocking the Kv1.3 ion channel have been demonstrated in pre-clinical models of autoimmune diseases. The specific and selective location of the Kv1.3 on the effector memory T cells makes it an attractive pharmaceutical target, as blocking preserves the protective effects of the rest of the immune system.
- PROGRAM ZP9830
- Preclinical
Development status
We have completed the pre-clinical activities with ZP9830 and the next step in development is to initiate a first-in-human clinical trial.
ZP9830 is an investigational compound whose safety and efficacy have not been evaluated or approved for marketing by any regulatory authority.
Chronic Inflammation
More about the disease area
Inflammation is a part of the body's natural defense system. However, when if it becomes chronic, inflammation can damage the body's tissue that inflammation normally works to heal.
